Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatocyte-like Cell Injection for Small-for-Size Syndrome
NCT07276568Phase 1Enrolling by invitation
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in small-for-size syndrome (SFSS) and liver failure (2 arms). Primary endpoints: Incidence of adverse events related to hepatocyte-like cell injection at 7 days, Plasma Ammonia at 3 months and 7 more. Started Dec 2025; status: enrolling by invitation.
02
Conditions
small-for-size syndrome (SFSS)liver failure
Beyond the preview
Go deeper on NCT07276568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276568.